Puri Fortes

Scientist fascinated by how noncoding RNAs impact biomedicine. Energy from family&friends. Love #noncodingRNA, believe in #RNAtherapy, live in @CIMA_unav

[nature @Nature]

The deaths of two children in separate gene-editing trials in China raise serious questions about oversight and could have a profound effect on the country’s biomedical industry

https://t.co/7KtPNIqBpy

[Sholto David @addictedtoigno1]

A few months ago I was browsing google images looking at p53 western blots in the SK-OV-3 cell line for an unrelated project. I noticed an unusual western blot hosted on Thermo Fisher's website which I posted on social media. Usually I just post weird blots to PubPeer. 👇

[Puri Fortes @FortesLab]

Thanks Thermo Fisher. Never again.

[Florian @fvderop]

"More than 18,000 questionable images found in antibody catalogues of 15 companies" - It's stuff like this that makes bio research so slow

[Puri Fortes @FortesLab]

Un equipazo!

[ADItech - Coordinador Sistema Navarro de I+D+i @ADItech]

#ALBA | Identificación de microproteínas (MPs) para generar vacunas contra el cáncer.

👉Proyecto estratégico financiado por @gob_na
👨‍💻 Coordinador: @CIMA_unav
🤝Socios: @navarrabiomed, #HUN, @ClinicaNavarra, #NNBi, @nucaps_nano, @NASERTIC y #ADItech

https://t.co/vJGNq9PjVh

[Nicholas Hornstein @GIMedOnc]

China approves the world’s first CAR-T therapy for a solid tumor.

Hours later, the FDA responds with full approval of afami-cel and expansion into pediatric synovial sarcoma.

A remarkable day for cellular therapy.

🇨🇳 Satri-cel (CLDN18.2 CAR-T)
CT041-ST-01, refractory gastric/GEJ cancer

• PFS: 3.25 vs 1.77 months (HR 0.37)
• OS: 7.9 vs 5.5 months (HR 0.69)
• 18-month OS: 20.1% vs 8.6%
• First CAR-T ever approved for a solid tumor

🇺🇸 Afami-cel (MAGE-A4 TCR-T)
SPEARHEAD-1, advanced synovial sarcoma

• ORR: 43%
• CR: 4.5%
• Median DoR: 6.0 months
• Median OS: 15.4 months
• First FDA-approved engineered cellular therapy for a solid tumor

For decades, solid tumors were where cellular therapies went to fail.

Now, on the same day, regulators in China and the United States have approved two different engineered T-cell platforms for two different solid tumors.

A brave new world for solid tumor oncology.

Any cancer center not providing cellular therapies is going to be left in the dust.

@OncoAlert @TheGutOncLab @Onco_Nexus

[Peter Ly @PeterLyLab]

Excited to share our latest paper, out today @CellCellPress. We found that large pieces of the human genome can transfer between cells upon direct contact, endowing recipient cells with heritable phenotypic changes. (1/7)

https://t.co/SbshGhofN0

[Marta Montes @MartaMontes3]

What a nice place for the #Ribored2026!

[Puri Fortes @FortesLab]

Super nice! Congrats!!!

[F. Moreno-Herrero @FMorenoHerrero]

Our latest work is out in Nucleic Acids Research @OxfordJournals We introduce Optical Tweezers Curtains: a method to study interactions between proteins and DNA-ends at the single-molecule level. @CNB_CSIC @SDeBraganca https://t.co/RyxkYoFynD

[Puri Fortes @FortesLab]

Amazing talk and incredible visit today from @AgamiLab. RNA translation is full of surprises!!! Million thanks Reuven!

[Cima Universidad de Navarra @CIMA_unav]

Today we welcome Dr. Reuven Agami (@NKI_nl), who will present: “When Mistranslation Meets Immunotherapy” organized by @FortesLab and @MaiteHuarteLab
A leading expert in #oncogenomics, his work has pioneered genetic tools to uncover how gene regulation drives #cancer.

[The Aptamer Society @AptamerSociety]

#AptOx26 starting tomorrow - 23rd March - at St Edmund Hall, #Oxford. Vew agenda here:

https://t.co/h7RmRUykRS

[Apadrina la Ciencia @ApadrinaCiencia]

📢 Los fondos son limitados. Ayúdanos a que #científicas en países de desarrollo tengan los recursos que merecen. ¡Cualquier aporte hasta 50€ se multiplica!!
👉¡Dona aquí!
https://t.co/78I98WHDaq

[Puri Fortes @FortesLab]

Super nice story! Do not miss this! I am still amazed about how a small protein extension can turn PTMA protein into more oncogenic! It is great to collaborate with the great Mar Alba lab! Mar… will there be a third preprint this month? 😳

[Mar Albà @maralbasoler]

Second preprint of the month!

Analysis of stop-loss mutations in > 20,000 cancer samples shows that several oncogenes and tumor suppressor genes are recurrently mutated. Another fruitful collaboration with @FortesLab @GRIB_Barcelona

https://t.co/vEDdyc98M3

[Mar Albà @maralbasoler]

New preprint from the group!

Here we use Nanopore dRNA and Ribo-Seq data from multiple yeast species to discover tens of highly conserved microproteins encoded by uORFs in polycistronic transcripts/alternative isoforms. @the_prbb

https://t.co/Z0pKqBYaCa

[Cima Universidad de Navarra @CIMA_unav]

"Zorevunersen es el primer tratamiento diseñado para actuar específicamente sobre la causa de #Dravet". Nuestro científico Rubén Hernández comenta en
@elmundosalud los resultados de un estudio internacional publicado en @NEJM
📰 Un reportaje de @cglucio
https://t.co/YmesI08MWf

[nature @Nature]

Nature research paper: GlycoRNA complexed with heparan sulfate regulates VEGF-A signalling

https://t.co/dJ7FVVlavU

[Molecular Cell @MolecularCell]

Online Now: Why m⁶A? An RNA surveillance model https://t.co/nLEQK2xtBU

[Puri Fortes @FortesLab]

Congrats!!! Even mooore work!

[Igor Ulitsky @IgorUlitsky]

Busy times ahead. I apologize in advance for potentially taking longer to respond to e-mails for a few years...

[Christine Mayr @Mayr_Christine]

More than 2700 3′UTRs are highly conserved.

These 3′UTRs are essential components in mRNA templates, as their deletion decreases protein activity without changing protein abundance.

Highly conserved 3′UTRs help the folding of proteins with long IDRs.

https://t.co/b6hd4AlIoX

[Puri Fortes @FortesLab]

Super nice! Congrats

[Marta Montes @MartaMontes3]

Very happy to share our work in collaboration with @MaiteHuarteLab @ElenaGrossi8 @CIMA_unav. Congratulations to all the people involved. It's been a long journey! https://t.co/KUcqEoiGB6

[Puri Fortes @FortesLab]

Las terapias de RNA… nos pueden llevar hasta el infinito y mas alla!

[CaixaResearch @CaixaResearch]

1/ El ARN nos abrió la puerta a las vacunas contra la COVID-19 en tiempo récord.💉

Las terapias de ARN prometen transformar la medicina, pero… ¿Hasta dónde nos pueden llevar?🤔

4️⃣ investigadores de la red #CaixaResearch nos lo explican:👇

https://t.co/V5GxhanWae